Sun Pharma Advanced Research Company (SPARC) is a pure-play drug discovery engine - it does not manufacture or sell medicines itself, but invents new ones and hands them to partners. It was spun out of Sun Pharmaceutical Industries in 2006 to house the group’s most ambitious research, and has since deliberately transformed from a drug-delivery tweaker into a modern biotech that creates first-in-class chemical and biological therapies for cancer and autoimmune diseases. Everything it does is shaped by a single operating philosophy: build a high-quality in-house translational engine, then use ruthless data stage-gates to “kill early, kill completely” - terminating weak programs cheaply so that capital and talent flow only to the most promising assets.
Business segments
A single research engine, organised around two therapeutic areas and a portfolio of partnered legacy products - oncology and immunology programmes are the future, while out-licensed commercial products generate milestone and royalty income to help fund the science.
1. Oncology platforms: the company’s bet on first-in-class cancer therapies
SPARC builds modular, scalable platform technologies that attack cancer through multiple mechanisms - antibody-drug conjugates, immune-stimulating conjugates, T-cell engagers, small-molecule drug conjugates and DNA-damage-repair inhibitors - so that a breakthrough in one can be replicated across others.
- Lead biologic asset targets a tumour protein others missed - SBO-154 is a first-in-class antibody-drug conjugate (ADC) that binds to the SEA domain of MUC1, a protein found on breast, lung, ovarian and pancreatic tumours; because the SEA domain is not shed into the bloodstream, the drug avoids the “sink effect” that defeated earlier MUC1 attempts and delivers its cell-killing payload directly to cancer cells. Phase 1 trials are active across eleven sites in the USA, Australia and India.
- Immune-stimulating conjugates turn tumours against themselves - the ISAC platform uses the same MUC1-SEA targeting to deliver proprietary STING agonists that activate the innate immune system, with pre-clinical proof-of-concept already achieved in mice that lack a full adaptive immune response.
- T-cell engagers designed for safety - SPARC’s TCE platform replaces part of the antibody with human serum albumin to extend half-life and is engineered to preferentially activate CD8+ killer T-cells, aiming to limit the cytokine-release syndrome that plagues earlier T-cell engagers.
- A spin-out turns a prostate-cancer asset into equity - SCO-155/TILR-097, a small-molecule drug conjugate developed with the University of California, San Francisco, was licensed to Tiller Therapeutics, a stealth-stage biotech; SPARC can earn up to a 55% equity stake in Tiller in exchange, letting external capital fund the first clinical trial in metastatic prostate cancer while SPARC retains upside.
- DNA-damage-repair inhibitors chase synthetic lethality - the DDR programme has two leads: one that makes tumours more sensitive to chemo and radiation, and another that overcomes PARP-inhibitor resistance, with strong tumour-growth inhibition shown in BRCA1-mutant triple-negative breast cancer models.
2. Immunology and dermatology: safer alternatives to black-box drugs
SPARC targets autoimmune skin diseases with non-JAK-pathway therapies, aiming to match the efficacy of JAK inhibitors without the class-wide black-box warning that limits their use.
- A first-in-class topical foam for alopecia areata - SCD-153 is a prodrug of an itaconate analogue, developed with Johns Hopkins University, that is applied directly to the scalp as a foam to avoid the systemic side effects of oral JAK inhibitors; it has completed a Phase 1a study in healthy volunteers and is now in a Phase 1b trial in alopecia-areata patients in India. The same mechanism is being explored for vitiligo, with a clinical study planned.
- An oral S1PR1 agonist licensed to the parent company - Vibozilimod (SCD-044) is a highly selective sphingosine-1-phosphate receptor agonist that avoids the S1PR3 activity linked to cardiac side effects in earlier drugs like fingolimod; a pooled safety analysis across 125 patients allowed most extensive cardiac monitoring to be removed. Sun Pharma is running two separate Phase 2 studies in atopic dermatitis and psoriasis, and SPARC is eligible for milestone payments on certain outcomes.
3. Partnered and commercialised products: royalties that fund the lab
SPARC earns money without a sales force - it invents a drug, gets it approved, then out-licenses it to a commercial partner in exchange for upfront payments, milestones and tiered royalties on sales.
- Sezaby: the only approved neonatal-seizure drug in the US - this benzyl-alcohol-free and propylene-glycol-free formulation of phenobarbital was licensed to a Sun Pharma subsidiary for US commercialisation in 2022, earning SPARC a $10 million upfront payment and a $5 million launch milestone. The FDA granted a Rare Pediatric Disease Priority Review Voucher, which SPARC agreed to sell for $195 million in April 2026.
- PDP-716: a once-a-day glaucoma drop awaiting a second chance - this brimonidine formulation met all Phase 3 endpoints against a three-times-daily comparator, but the FDA issued a Complete Response Letter over manufacturing-facility issues, not clinical ones; SPARC’s partner Ocuvex Therapeutics resubmitted the application in November 2025 after an alternate API supplier was qualified.
- Elepsia XR: a seizure drug with tiered royalties up to 50% - this extended-release levetiracetam tablet, approved by the FDA, is commercialised in the US by Tripoint Therapeutics; SPARC earns royalties of 15% to 50% of net sales, though an import alert at the partner’s manufacturing site has disrupted supply and a technology transfer to a new CMO is underway.
Technology platforms and capabilities
SPARC’s competitive advantage rests on a captive, multi-modal R&D engine that spans discovery through clinical development - it is not a virtual biotech outsourcing everything to contractors.
- In-house biologics capability built from scratch - the company can engineer traditional antibodies, ADCs, bispecifics and multispecifics, and scale them to the clinic without relying on external partners for the core science.
- Proprietary drug-delivery technologies - TearAct enables once-a-day ocular dosing, Lipixelle solubilises ophthalmic drugs without the preservative BAK (which damages the eye surface over long-term use), and Wrap Matrix reduces pill size for high-dose oral drugs.
- India’s patient pool as a strategic asset - SPARC uses Indian clinical-trial infrastructure to generate quick proof-of-concept and biomarker data cost-effectively, compressing timelines before committing to expensive global studies.
- A leaner, consolidated footprint - after discontinuing the Vodobatinib Parkinson’s programme, the company cut headcount by 40% overall and over 80% in the US, consolidated labs from four sites to two in Baroda, and shifted to a hybrid model with more outsourcing, saving roughly $10 million a year.
Group structure and partners
SPARC is a publicly listed company controlled by the promoter group behind Sun Pharma, with a web of licensing deals that turn its science into revenue while keeping its own balance sheet light.
- The promoter and promoter group held 65.67% of the equity as of January 2026, with Shanghvi Finance Private Limited as the largest corporate shareholder; a preferential warrant issue approved that month would raise the group’s stake to 69.31% upon conversion.
- Two wholly owned subsidiaries support operations: SPARCLIFE Inc. in Delaware coordinates US clinical trials, and Genokine Biotech Limited in Gujarat handles R&D services including veterinary and agricultural product development.
- Key commercial relationships include Sun Pharma (Vibozilimod global rights, Sezaby US rights), Ocuvex Therapeutics (PDP-716 and SDN-037 global rights ex-India and Greater China), Tripoint Therapeutics (Elepsia XR US rights), and Tiller Therapeutics (SCO-155/TILR-097 worldwide license).
- A Master License Agreement with Sun Pharmaceutical Industries Inc. provides that the net-present-value split from commercialised products shall be agreed by the parties, and shall not be less than 10% and not more than 40% in favour of SPARC, plus royalties on net sales.
- The company had approximately $46 million in debt outstanding against a $125 million approved limit as of Q3 FY26, with additional promoter-supported debt available to fund the pipeline.